New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
06:17 EDTICPTIntercept initiated with a Neutral at Goldman
Goldman Sachs started shares of Intercept with a Neutral rating saying it's difficult to value the company's obeticholic acid for the treatment of nonalcoholic steatohepatitis without the FLINT trial data, which is due out later this year. Goldman put a $265 price target on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
17:05 EDTICPTOrbiMed reports 7% stake in Intercept
Subscribe for More Information
August 26, 2014
07:46 EDTICPTIntercept Pharmaceuticals volatility at low end of historic range
Subscribe for More Information
August 18, 2014
10:57 EDTICPTOptions with decreasing implied volatility
Subscribe for More Information
August 15, 2014
17:02 EDTICPTStocks end week slightly higher despite flare-up in Russian tensions
Subscribe for More Information
10:41 EDTICPTOptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT UVXY MNKD KING VIX SVXY VXX RAX OPK
10:01 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:32 EDTICPTIntercept started with Underperform, $172 target at FBR Capital
FBR Capital initiated shares of Intercept with an Underperform rating and $172 price target. The stock closed yesterday at $296.36. FBR believes investors are too optimistic on the nonalcoholic steatohepatitis market and the company's path to commercialization for its obeticholic acid. The firm thinks Intercept may face payor pushback and restriction as its drug will be competing with hepatitis C treatments for dollars.
06:16 EDTICPTIntercept initiated with an Underperform at FBR Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use